Giving immunotherapy earlier in the day can significantly extend patients' survival, compared to giving treatment later in the day, a new study of lung cancer shows.

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...

TROPION-Lung17 Clinical Update: What Investors Should Watch in AstraZeneca and Daiichi Sankyo’s Next Lung Cancer Catalyst ...

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its ...

Cancer care has long focused on what drugs to give and in what doses, but a growing body of evidence suggests the clock on the wall may be just as important. Researchers are finding that the hour a ...

Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer is generally the top cause of cancer-related death globally and in the United States (US). In the US in 2023, lung cancer ...

In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...